Focused on developing therapies for blood-based disorders, the company built its pipeline around treatments for sickle cell disease, including the approved drug Oxbryta. Its clinical progress and regulatory milestones made it a closely watched small-cap biotechnology name among healthcare investors....
2 members of Congress have disclosed 3 trades in Global Blood Therapeutics, Inc. (GBT), a Healthcare company. The buy/sell breakdown shows 2 purchases versus 1 sale, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2019-06-24 | Donna Shalala | sell | $1K – $15K |
| 2019-06-04 | Donna Shalala | buy | $1K – $15K |
| 2016-09-15 | MICHAEL T. MCCAUL | buy | $1K – $15K |